https://www.selleckchem.com/products/cynarin.html
The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19. We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated. Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients
Like
Comment
Share
